Martin Maron to Cardiovascular Agents
This is a "connection" page, showing publications Martin Maron has written about Cardiovascular Agents.
Connection Strength
1.558
-
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 05 30; 390(20):1849-1861.
Score: 0.850
-
Maron MS. My approach to clinical management of hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2014 Oct; 24(7):314-5.
Score: 0.430
-
Maron BJ, Maron MS, Sherrid MV, Rowin EJ. Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2022 05 03; 11(9):e024566.
Score: 0.185
-
Spoladore R, Maron MS, D'Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J. 2012 Jul; 33(14):1724-33.
Score: 0.093